Stock Scorecard
Stock Summary for Vir Biotechnology Inc (VIR) - $5.78 as of 11/13/2025 9:40:25 AM EST
Total Score
13 out of 30
Safety Score
36 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for VIR
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for VIR
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for VIR
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for VIR
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for VIR (36 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 5 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for VIR
Financial Details for VIR
Company Overview |
|
|---|---|
| Ticker | VIR |
| Company Name | Vir Biotechnology Inc |
| Country | USA |
| Description | Vir Biotechnology, Inc. is a clinical-stage immunology company headquartered in San Francisco, California, focused on leveraging its proprietary technologies to develop therapeutic solutions for serious infectious diseases. With a robust pipeline targeting viral pathogens, including its innovative monoclonal antibodies and immunotherapeutics, Vir aims to address unmet medical needs in areas such as COVID-19 and influenza. The company's strategic partnerships and collaborations enhance its research capabilities, positioning it as a key player in the biotechnology sector dedicated to improving global health outcomes. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 5.78 |
| Price 4 Years Ago | 41.87 |
| Last Day Price Updated | 11/13/2025 9:40:25 AM EST |
| Last Day Volume | 1,318,660 |
| Average Daily Volume | 1,488,683 |
| 52-Week High | 14.45 |
| 52-Week Low | 4.16 |
| Last Price to 52 Week Low | 38.94% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 41.29 |
| Sector PE | 114.99 |
| 5-Year Average PE | 2.26 |
| Free Cash Flow Ratio | 4.66 |
| Industry Free Cash Flow Ratio | 12.45 |
| Sector Free Cash Flow Ratio | 28.11 |
| Current Ratio Most Recent Quarter | 7.25 |
| Total Cash Per Share | 1.24 |
| Book Value Per Share Most Recent Quarter | 5.73 |
| Price to Book Ratio | 0.90 |
| Industry Price to Book Ratio | 32.90 |
| Sector Price to Book Ratio | 33.65 |
| Price to Sales Ratio Twelve Trailing Months | 44.31 |
| Industry Price to Sales Ratio Twelve Trailing Months | 24.58 |
| Sector Price to Sales Ratio Twelve Trailing Months | 14.00 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 5 |
Share Statistics |
|
| Total Shares Outstanding | 139,125,000 |
| Market Capitalization | 804,142,500 |
| Institutional Ownership | 80.58% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 58.50% |
| Annual Earnings Growth | 15.14% |
| Reported EPS 12 Trailing Months | -3.62 |
| Reported EPS Past Year | -2.85 |
| Reported EPS Prior Year | -3.82 |
| Net Income Twelve Trailing Months | -499,653,000 |
| Net Income Past Year | -521,960,000 |
| Net Income Prior Year | -615,061,000 |
| Quarterly Revenue Growth YOY | -89.90% |
| 5-Year Revenue Growth | 153.35% |
| Operating Margin Twelve Trailing Months | -72,268.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 172,299,000 |
| Total Cash Past Year | 222,947,000 |
| Total Cash Prior Year | 241,576,000 |
| Net Cash Position Most Recent Quarter | 172,299,000 |
| Net Cash Position Past Year | 222,947,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 1,150,385,000 |
| Total Stockholder Equity Prior Year | 1,590,236,000 |
| Total Stockholder Equity Most Recent Quarter | 796,098,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -464,281,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -3.34 |
| Free Cash Flow Past Year | -453,653,000 |
| Free Cash Flow Prior Year | -800,358,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.18 |
| MACD Signal | 0.21 |
| 20-Day Bollinger Lower Band | 4.38 |
| 20-Day Bollinger Middle Band | 5.30 |
| 20-Day Bollinger Upper Band | 6.23 |
| Beta | 1.35 |
| RSI | 49.90 |
| 50-Day SMA | 6.58 |
| 150-Day SMA | 11.90 |
| 200-Day SMA | 15.42 |
System |
|
| Modified | 11/11/2025 11:58:54 AM EST |